New research led by University of Colorado School of Medicine may lead to new targeted treatments for rheumatoid arthritis, an autoimmune disease that causes joint inflammation. The work of many researchers from the Accelerating Medicines Partnership: Rheumatoid Arthritis and Systemic Lupus Erythematosus Network collected inflamed tissue from 70 patients with RA and revealed six different subgroups of RA based on their cellular makeup.
The data could help discover new treatment targets for rheumatoid arthritis, ending the “guess-and-check” method of finding a treatment that works for individual patients. Powerful computational classification methods can identify which patients will respond to which treatments. The research finds that specific partners between different immune cells work together in different categories of RA, and interdisciplinary research and cross-institution effort were crucial in achieving these results.
This research is part of a multicenter consortium effort that began in 2018, funded by the National Institutes of Health and the Foundation for the National Institutes of Health. The findings might also be used to study other autoimmune diseases or immune responses to cancer or infection. The researchers hope to build new collaborations with faculty members across the CU Anschutz Medical Campus.
>>Join our Facebook Group be part of community. <<